-
Arruti M, Pineiro LD, Salicio Y, Cilla G, Goenaga MA, Lopez de Munain A, 2017: Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007-2014)[J]. J Neurovirol, 23, 451-459. doi: 10.1007/s13365-017-0519-y
-
Asada H, 2019: VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study[J]. Vaccine, 37, 6776-6781. doi: 10.1016/j.vaccine.2019.09.031
-
Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, Lopez-Jimenez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM, Collaborators Z-HSG, 2019: Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial[J]. JAMA, 322, 123-133. doi: 10.1001/jama.2019.9053
-
Berarducci B, Ikoma M, Stamatis S, Sommer M, Grose C, Arvin AM, 2006: Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection[J]. J Virol, 80, 9481-9496. doi: 10.1128/JVI.00533-06
-
Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC, Zoster HZsSG, 2015: Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study[J]. J Infect Dis, 211, 1279-1287. doi: 10.1093/infdis/jiu606
-
Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM, 2011: CpG DNA as a vaccine adjuvant[J]. Expert Rev Vaccines, 10, 499-511. doi: 10.1586/erv.10.174
-
Breuer J, 2018: Molecular genetic insights into varicella zoster virus (VZV), the vOka vaccine strain, and the pathogenesis of latency and reactivation[J]. J Infect Dis, 218, S75-S80. doi: 10.1093/infdis/jiy279
-
Cheng MP, Quach C, Marty FM, 2020: Herpes zoster subunit vaccination for renal transplant recipients[J]. Clin Infect Dis, 70, 718-719.
-
Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC, 2013: Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age[J]. J Infect Dis, 208, 1953-1961. doi: 10.1093/infdis/jit365
-
Cohen JI, 2015: A new vaccine to prevent herpes zoster[J]. N Engl J Med, 372, 2149-2150. doi: 10.1056/NEJMe1505050
-
Cui S, Wang Y, Gong Y, Lin X, Zhao Y, Zhi D, Zhou Q, Zhang S, 2018: Correlation of the cytotoxic effects of cationic lipids with their headgroups[J]. Toxicol Res (Camb), 7, 473-479. doi: 10.1039/C8TX00005K
-
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC, Group ZOES, 2016: Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older[J]. N Engl J Med, 375, 1019-1032. doi: 10.1056/NEJMoa1603800
-
Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ, Group ZOES, 2018: Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older[J]. J Infect Dis, 217, 1750-1760. doi: 10.1093/infdis/jiy095
-
Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL, 2012: Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice[J]. Vaccine, 30, 3126-3135. doi: 10.1016/j.vaccine.2012.01.088
-
Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, Garcon N, Van Mechelen M, Morel S, 2014: Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells[J]. J Immunol, 193, 1920-1930. doi: 10.4049/jimmunol.1400948
-
Gao J, Ochyl LJ, Yang E, Moon JJ, 2017: Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens[J]. Int J Nanomed, 12, 1251-1264. doi: 10.2147/IJN.S125866
-
Garcia-Valcarcel M, Fowler WJ, Harper DR, Jeffries DJ, Layton GT, 1997: Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoprotein E (gE)[J]. Vaccine, 15, 709-719. doi: 10.1016/S0264-410X(96)00228-9
-
Garnett GP, Grenfell BT, 1992: The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster[J]. Epidemiol Infect, 108, 513-528. doi: 10.1017/S0950268800050019
-
Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, Azrolan N, Sutradhar SC, Wang WW, Chan IS, Schlienger K, Schodel F, Silber JL, Zostavax Protocol 010 Study G, 2008: A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax[J]. Clin Vaccine Immunol, 15, 314-319. doi: 10.1128/CVI.00310-07
-
Gwak SJ, Yun Y, Yoon DH, Kim KN, Ha Y, 2016: Therapeutic use of 3beta-[N-(N', N'-dimethylaminoethane) carbamoyl] cholesterol-modified PLGA nanospheres as gene delivery vehicles for spinal cord injury[J]. PLoS ONE, 11, e0147389-. doi: 10.1371/journal.pone.0147389
-
Haberthur K, Engelmann F, Park B, Barron A, Legasse A, Dewane J, Fischer M, Kerns A, Brown M, Messaoudi I, 2011: CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection[J]. PLoS Pathog, 7, e1002367-. doi: 10.1371/journal.ppat.1002367
-
Haumont M, Jacquet A, Massaer M, Deleersnyder V, Mazzu P, Bollen A, Jacobs P, 1996: Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells[J]. Virus Res, 40, 199-204. doi: 10.1016/0168-1702(95)01270-2
-
Jain NK, Sahni N, Kumru OS, Joshi SB, Volkin DB, Russell Middaugh C, 2015: Formulation and stabilization of recombinant protein based virus-like particle vaccines[J]. Adv Drug Deliv Rev, 93, 42-55. doi: 10.1016/j.addr.2014.10.023
-
Krause PR, Klinman DM, 2000: Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children[J]. Nat Med, 6, 451-454. doi: 10.1038/74715
-
Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, Haas JG, Johnston C, Wald A, Koelle DM, 2015: Zoster vaccination increases the breadth of CD4 + T cells responsive to varicella zoster virus[J]. J Infect Dis, 212, 1022-1031. doi: 10.1093/infdis/jiv164
-
Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeliere P, Vassilev V, Ledent E, Heineman TC, 2012: A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults[J]. J Infect Dis, 206, 1280-1290. doi: 10.1093/infdis/jis497
-
Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw KL, Willis E, Curtis JR, 2017: Studies with herpes zoster vaccines in immune compromised patients[J]. Expert Rev Vaccines, 16, 1217-1230. doi: 10.1080/14760584.2017.1395703
-
Levin MJ, Cai GY, Lee KS, Rouphael NG, Mehta AK, Canniff J, Mulligan MJ, Weinberg A, 2018a: Varicella-zoster virus DNA in blood after administration of herpes zoster vaccine[J]. J Infect Dis, 217, 1055-1059. doi: 10.1093/infdis/jix653
-
Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A, 2018b: Th1 memory differentiates recombinant from live herpes zoster vaccines[J]. J Clin Invest, 128, 4429-4440. doi: 10.1172/JCI121484
-
Liu C, Yao Y, Yang X, Bai H, Huang W, Xia Y, Ma Y, 2015: Production of recombinant human papillomavirus type 52 L1 Protein in Hansenula polymorpha formed virus-like particles[J]. J Microbiol Biotechnol, 25, 936-940. doi: 10.4014/jmb.1412.12027
-
Liu L, Cao F, Liu X, Wang H, Zhang C, Sun H, Wang C, Leng X, Song C, Kong D, Ma G, 2016a: Hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticles as a nanovaccine induce robust humoral and cellular immune responses[J]. ACS Appl Mater Interfaces, 8, 11969-11979. doi: 10.1021/acsami.6b01135
-
Liu L, Ma P, Wang H, Zhang C, Sun H, Wang C, Song C, Leng X, Kong D, Ma G, 2016b: Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles[J]. J Control Release, 225, 230-239. doi: 10.1016/j.jconrel.2016.01.050
-
Liu C, Chu X, Sun P, Feng X, Huang W, Liu H, Ma Y, 2018a: Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model[J]. Hum Vaccin Immunother, 14, 931-940. doi: 10.1080/21645515.2017.1420446
-
Liu C, Chu X, Yan M, Qi J, Liu H, Gao F, Gao R, Ma G, Ma Y, 2018b: Encapsulation of Poly I: C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors[J]. Int J Pharm, 553, 327-337. doi: 10.1016/j.ijpharm.2018.10.054
-
Mahalingam R, Messaoudi I, Gilden D, 2010: Simian varicella virus pathogenesis[J]. Curr Top Microbiol Immunol, 342, 309-321.
-
Malavige GN, Jones L, Black AP, Ogg GS, 2008: Varicella zoster virus glycoprotein E-specific CD4 + T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors[J]. Clin Exp Immunol, 152, 522-531. doi: 10.1111/j.1365-2249.2008.03633.x
-
Maurer T, Heit A, Hochrein H, Ampenberger F, O'Keeffe M, Bauer S, Lipford GB, Vabulas RM, Wagner H, 2002: CpG-DNA aided cross-presentation of soluble antigens by dendritic cells[J]. Eur J Immunol, 32, 2356-2364. doi: 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z
-
Moodley A, Swanson J, Grose C, Bonthius DJ, 2019: Severe herpes zoster following varicella vaccination in immunocompetent young children[J]. J Child Neurol, 10, 883073818821498-.
-
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study G, 2005: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults[J]. N Engl J Med, 352, 2271-2284. doi: 10.1056/NEJMoa051016
-
Romoren K, Thu BJ, Bols NC, Evensen O, 2004: Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin[J]. Biochim Biophys Acta, 1663, 127-134. doi: 10.1016/j.bbamem.2004.02.007
-
Rosenthal JA, Chen L, Baker JL, Putnam D, DeLisa MP, 2014: Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale[J]. Curr Opin Biotechnol, 28, 51-58. doi: 10.1016/j.copbio.2013.11.005
-
Sadaoka T, Depledge DP, Rajbhandari L, Venkatesan A, Breuer J, Cohen JI, 2016: In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency[J]. Proc Natl Acad Sci U S A, 113, E2403-E2412. doi: 10.1073/pnas.1522575113
-
Seder RA, Ahmed R, 2003: Similarities and differences in CD4 + and CD8 + effector and memory T cell generation[J]. Nat Immunol, 4, 835-842. doi: 10.1038/ni969
-
Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, El Idrissi M, Heineman TC, Berkowitz EM, 2014: A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients[J]. Blood, 124, 2921-2929. doi: 10.1182/blood-2014-04-573048
-
Steain M, Sutherland JP, Rodriguez M, Cunningham AL, Slobedman B, Abendroth A, 2014: Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia[J]. J Virol, 88, 2704-2716. doi: 10.1128/JVI.03445-13
-
Uebe B, Sauerbrei A, Burdach S, Horneff G, 2002: Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child[J]. Eur J Pediatr, 161, 442-444. doi: 10.1007/s00431-002-0981-1
-
Upadhyay S, Jeena GS, Shikha Shukla RK, 2018: Recent advances in steroidal saponins biosynthesis and in vitro production[J]. Planta, 248, 519-544.
-
Varga SM, Selin LK, Welsh RM, 2001: Independent regulation of lymphocytic choriomeningitis virus-specific T cell memory pools: relative stability of CD4 memory under conditions of CD8 memory T cell loss[J]. J Immunol, 166, 1554-1561. doi: 10.4049/jimmunol.166.3.1554
-
Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, Lopez-Fauqued M, Salaun B, Heineman TC, Oostvogels L, Zoster-028 Study G, 2019: Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial[J]. Cancer, 125, 1301-1312. doi: 10.1002/cncr.31909
-
Weinberg A, Levin MJ, 2010: VZV T cell-mediated immunity[J]. Curr Top Microbiol Immunol, 342, 341-357.
-
Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Levin MJ, 2018: Comparative immune responses to licensed herpes zoster vaccines[J]. J Infect Dis, 2018, S81-S87.
-
Wroblewska Z, Valyi-Nagy T, Otte J, Dillner A, Jackson A, Sole DP, Fraser NW, 1993: A mouse model for varicella-zoster virus latency[J]. Microb Pathog, 15, 141-151. doi: 10.1006/mpat.1993.1064
-
Wu Y, Zhu R, Xu L, Li Y, Li S, Yu H, Li S, Zhu H, Cheng T, Xia N, 2017: A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus[J]. Vaccine, 35, 2728-2735. doi: 10.1016/j.vaccine.2017.03.065
-
Wui SR, Kim KS, Ryu JI, Ko A, Do HTT, Lee YJ, Kim HJ, Lim SJ, Park SA, Cho YJ, Kim CG, Lee NG, 2019: Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice[J]. Vaccine, 37, 2131-2141. doi: 10.1016/j.vaccine.2019.02.048
-
Zhu R, Liu J, Chen C, Ye X, Xu L, Wang W, Zhao Q, Zhu H, Cheng T, Xia N, 2016: A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice[J]. Vaccine, 34, 1589-1596. doi: 10.1016/j.vaccine.2016.02.007